Introduction: Non-Specific knee effusion is a disease secondary to degenerative changes/excessive body weight/excessive wear tear
/trivial or evident trauma to the knee joint or condition associated Non-specific arthropathies. The condition can be defined as the
abnormal accumulation of the fluid in the knee capsule or the adjoining supra-patellar bursa secondary to the irritation/inflammation
of sub-acute strength in the joint synovium. kro??uka??r?a. as described in ayurveda, can be corelated with knee effusion. Present
clinical trial an effort has been made to evaluate anti-inflammatory effect of Commiphora-wightii and Boswellia serrata individually
in combination with Curcuma longa against Diclofenac potassium [NSAID’s] on Non-specific knee effusion.
Methodology: Thirty seven registered, clinically diagnosed patients of Non-specific knee effusion were selected for the present
clinical trial 7 patients failed to complete the study due to non-compliance of the protocol ,remaining 30 patients were assorted in to
three groups.For this purpose patients were alienated into three groups- A , B &C Group A (Trial Group I) -Ten patients were
given crude extract of Commiphora wightii 500 mg and Curcuma longa 500 mg in a separate capsules twice a day continuously for
8 weeks orally.Group B (Trial Group II) – Ten patients were given crude extract of Boswellia serrata 500 mg along with Curcuma
longa 500 mg in a separate capsules twice a daily continuously 8 weeks orally. Group C (Control Group) – Ten patients were given
Diclofenac Potassium 50 mg twice a day continuously for 2 weeks orally.
The patients of Group C (Control Group)were given the drug Diclofenac potassium only for two weeks in comparison to the drug
intervention of eight weeks in trial groups owing to its reported gastric irritation/inflammation.
Results: The results were assessed in terms of clinical parameters on first 30 patients who complete the study. 28 patients completely
recovered from their main symptoms. 2 patients also improved.
Result of Diclofenac potassium was significantly better in the outcomes in comparison to the trial drugs Shallaki, Guggulu and
Haridra when compared at the end of two weeks of start of the trial. Trial drugs Shallaki, Guggulu & Haridra are also having
outcomes of comparative extent to Diclofenac Potassium, When administered continuously for further 6 weeks i.e total 8 weeks.